Drug Profile
Research programme: aptamer-dicer substrate RNAi therapeutics - Archemix/Dicerna
Alternative Names: Aptamer-DsiRNALatest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Archemix Corporation; Dicerna Pharmaceuticals
- Class Oligonucleotides; RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 28 Dec 2021 Dicerna Pharmaceuticals has been acquired by Novo Nordisk
- 16 Nov 2012 Discontinued for Undefined indication in USA (Parenteral)
- 21 Jul 2009 Early research in Undefined indication in USA (Parenteral)